⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Beeline Medicines and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Beeline Medicines
↗Boston, USA
Beeline Medicines is a clinical-stage biotechnology company dedicated to developing precision therapies for autoimmune and inflammatory diseases. The company was formed in July 2025 and officially debuted in April 2026 with a portfolio of five programs in-licensed from Bristol Myers Squibb.
Headquartered in Boston, Massachusetts, the company is backed by a $300 million Series A financing led by Bain Capital. Its pipeline focuses on mechanistically guided small-molecule and biologic candidates designed to target upstream drivers of immune dysregulation, with the goal of providing durable, life-changing treatment options for patients with immune-mediated conditions.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2025
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$300M
Investors:Bain Capital
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Small molecule, Biologic
Active Trials:1
Trial Phases:Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Bristol Myers Squibb (Licensing agreement for five drug programs)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Saqib Islam - CEO
Daniel S. Lynch - Chairman of the Board
Board Members:Daniel S. Lynch, Nicholas Downing
LINKS
Website:beelinemedicines.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Beeline Medicines. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.